MedTrace Logo

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tofacitinib vs Abatacept

NCT04529876 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 29464

Last updated 2021-11-16

No results posted yet for this study

Summary

This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

Conditions

Interventions

DRUG

Tofacitinib

Tofacitinib claim is used as the reference group.

DRUG

Abatacept

Abatacept claim is used as the exposure group.

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Rutgers University

    collaborator OTHER

  • Johns Hopkins University

    collaborator OTHER

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Rishi J Desai, PhD · Brigham and Women's Hospital

  • Madhav Thambisetty, MD, PhD · National Institute on Aging (NIA)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-17
Primary Completion
2021-08-31
Completion
2021-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04529876 on ClinicalTrials.gov